Invivyd (NASDAQ:IVVD – Get Rating) had its price objective reduced by Morgan Stanley from $3.00 to $2.00 in a research note released on Tuesday morning, Benzinga reports. Morgan Stanley currently has an underweight rating on the stock.
Invivyd Trading Up 7.8 %
Shares of IVVD opened at $2.20 on Tuesday. Invivyd has a 1-year low of $1.42 and a 1-year high of $12.11. The firm has a market capitalization of $239.76 million, a PE ratio of -0.85 and a beta of -0.50. The company’s 50-day moving average is $1.97.
Invivyd (NASDAQ:IVVD – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.04. Equities analysts forecast that Invivyd will post -2.18 earnings per share for the current year.
Invivyd Company Profile
Invivyd, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.
- Get a free copy of the StockNews.com research report on Invivyd (IVVD)
- Is It Time To Get Aggressive With Defense Stocks?
- 3 Retail Stocks Ringing the Register in 2023
- When Will Crane Holdings Take Flight?
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.